Malignant solid neoplasm ERBB2-mutated · 4 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Trastuzumab deruxtecan monotherapy Variant #01 | ERBB2 | R 81 019 | 21d | ~15.5 mo | ~22.9 mo | ~23 | ~R 1 863 446 PFS proxy · indirect | 11 |
Pertuzumab and Trastuzumab Variant #02 | ERBB2 | R 74 512 | 21d | — | — | — | — | — |
Trastuzumab emtansine monotherapy Variant #01 | ERBB2 | R 41 405 | 21d | ~7.4 mo | ~29.9 mo | ~11 | ~R 455 454 PFS proxy · indirect | 7 |
Neratinib monotherapy N/A - secondary systemic drug | ERBB2 | R 62 | 28d | — | — | — | — | 1 |
4 of 4 regimens shown